Literature DB >> 23053744

Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis.

Valeria B Fernández Vallone1, Erica L Hofer, Hosoon Choi, Raúl H Bordenave, Emilio Batagelj, Leonardo Feldman, Vincent La Russa, Daniela Caramutti, Federico Dimase, Vivian Labovsky, Leandro M Martínez, Norma A Chasseing.   

Abstract

Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to-mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 % of advanced breast cancer patients and 30-40 % of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.

Entities:  

Mesh:

Year:  2012        PMID: 23053744     DOI: 10.1007/s10585-012-9539-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  69 in total

1.  Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability.

Authors:  Zhinong Huang; Pei-Gen Ren; Ting Ma; R Lane Smith; Stuart B Goodman
Journal:  Cytokine       Date:  2010-06-26       Impact factor: 3.861

2.  Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.

Authors:  Ya-Ling Hsu; Ming-Shyan Huang; Chih-Jen Yang; Jen-Yu Hung; Ling-Yu Wu; Po-Lin Kuo
Journal:  J Biol Chem       Date:  2011-09-01       Impact factor: 5.157

3.  Alteration on the expression of IL-1, PDGF, TGF-beta, EGF, and FGF receptors and c-Fos and c-Myc proteins in bone marrow mesenchymal stroma cells from advanced untreated lung and breast cancer patients.

Authors:  Erica Leonor Hofer; Vincent La Russa; Alba Elizabeth Honegger; Eduardo Oscar Bullorsky; Raúl Horacio Bordenave; Norma Alejandra Chasseing
Journal:  Stem Cells Dev       Date:  2005-10       Impact factor: 3.272

Review 4.  The vascular niche: home for normal and malignant hematopoietic stem cells.

Authors:  P L Doan; J P Chute
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

5.  Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation.

Authors:  S P Bruder; N Jaiswal; S E Haynesworth
Journal:  J Cell Biochem       Date:  1997-02       Impact factor: 4.429

6.  Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny.

Authors:  H Castro-Malaspina; R E Gay; G Resnick; N Kapoor; P Meyers; D Chiarieri; S McKenzie; H E Broxmeyer; M A Moore
Journal:  Blood       Date:  1980-08       Impact factor: 22.113

7.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

8.  Matrix metalloprotease activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior.

Authors:  Grit Kasper; Juliane D Glaeser; Sven Geissler; Andrea Ode; Jens Tuischer; Georg Matziolis; Carsten Perka; Georg N Duda
Journal:  Stem Cells       Date:  2007-05-10       Impact factor: 6.277

Review 9.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

10.  Higher oxidation and lower antioxidant levels in peripheral blood plasma and bone marrow plasma from advanced cancer patients.

Authors:  Elena M V de Cavanagh; Alba E Honegger; Erica Hofer; Raul H Bordenave; Eduardo O Bullorsky; Norma A Chasseing; Cesar Fraga
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

View more
  7 in total

1.  Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases.

Authors:  Leandro Marcelo Martinez; Valeria Beatriz Fernández Vallone; Vivian Labovsky; Hosoon Choi; Erica Leonor Hofer; Leonardo Feldman; Raúl Horacio Bordenave; Emilio Batagelj; Federico Dimase; Ana Rodriguez Villafañe; Norma Alejandra Chasseing
Journal:  Clin Exp Metastasis       Date:  2013-10-31       Impact factor: 5.150

2.  Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.

Authors:  Oshrat Attar-Schneider; Victoria Zismanov; Liat Drucker; Maya Gottfried
Journal:  Tumour Biol       Date:  2015-10-30

3.  In vivo gene activity of human mesenchymal stem cells after scaffold-mediated local transplantation.

Authors:  Soon Jung Hwang; Tae Hyung Cho; In Sook Kim
Journal:  Tissue Eng Part A       Date:  2014-04-28       Impact factor: 3.845

Review 4.  Targeting tumor-stromal interactions in bone metastasis.

Authors:  Mark Esposito; Yibin Kang
Journal:  Pharmacol Ther       Date:  2013-10-15       Impact factor: 12.310

Review 5.  Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.

Authors:  María Cecilia Sanmartin; Francisco Raúl Borzone; María Belén Giorello; Gustavo Yannarelli; Norma Alejandra Chasseing
Journal:  Front Bioeng Biotechnol       Date:  2022-04-14

Review 6.  The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.

Authors:  Binnaz Demirkan
Journal:  J Clin Med       Date:  2013-11-22       Impact factor: 4.241

7.  [Investigational Study of Mesenchymal Stem Cells on Lung Cancer Cell Proliferation and Invasion].

Authors:  Mei Li; Yi Wu; Renwang Liu; Lili Guo; Tingting Xu; Jun Chen; Song Xu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.